scPharmaceuticals Inc. Enters Material Definitive Agreement
| Field | Detail |
|---|---|
| Company | Scpharmaceuticals Inc. |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
Related Tickers: SCPH
TL;DR
SCPH inked a big deal, filing an 8-K on 8/20/25.
AI Summary
On August 20, 2025, scPharmaceuticals Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and its principal executive offices are located in Burlington, Massachusetts.
Why It Matters
This filing indicates a significant new agreement for scPharmaceuticals Inc., which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-38293 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5184075 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- scPharmaceuticals Inc. (company) — Registrant
- August 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Burlington, Massachusetts (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by scPharmaceuticals Inc.?
The filing states that scPharmaceuticals Inc. entered into a material definitive agreement on August 20, 2025, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 20, 2025.
Where are scPharmaceuticals Inc.'s principal executive offices located?
scPharmaceuticals Inc.'s principal executive offices are located at 25 Mall Road, Suite 203, Burlington, Massachusetts, 01803.
What is the company's state of incorporation?
scPharmaceuticals Inc. is incorporated in Delaware.
What is the SEC file number for scPharmaceuticals Inc.?
The SEC file number for scPharmaceuticals Inc. is 001-38293.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-08-25 06:02:34
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share SCPH The Nasdaq Global Se
Filing Documents
- d931746d8k.htm (8-K) — 27KB
- d931746dex101.htm (EX-10.1) — 20KB
- 0001193125-25-186947.txt ( ) — 162KB
- scph-20250820.xsd (EX-101.SCH) — 3KB
- scph-20250820_lab.xml (EX-101.LAB) — 18KB
- scph-20250820_pre.xml (EX-101.PRE) — 11KB
- d931746d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Amendment 1 to the Supply Agreement, dated August 20, 2025, by and between West Pharmaceutical Services, Inc. and the Registrant 104 Cover Page Interactive Data File (embedded within the inline XBRL document) * Portions of this exhibit (indicated by asterisks) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCPHARMACEUTICALS INC. Date: August 25, 2025 By: /s/ John H. Tucker Name: John H. Tucker Title: President and Chief Executive Officer